A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
Completed · Phase 1/Phase 2
Conditions studied: HIV/AIDS
In brief
This is a Phase 1/2a open label study to evaluate the safety, tolerability, pharmacokinetics and anti-viral activity of PGT121, VRC07-523LS and PGDM1400 for HIV prevention and therapy.
Key facts
- Study ID
- NCT03721510
- Run by
- International AIDS Vaccine Initiative
- People needed
- 19
- Starts
- 2018-12-03
- Expected to finish
- 2022-05-02
- Last updated by the study team
- 2022-05-10
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orlando Immunology Center — Orlando, Florida, United States
- Center for Virology and Vaccine Research/ Clinical Trials Unit/ BIDMC — Boston, Massachusetts, United States
- Houston AIDS Research Team (HART) — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.